dr. kahl on frontline btk inhibitor selection in cll
Published 4 years ago • 210 plays • Length 1:53Download video MP4
Download video MP3
Similar videos
-
1:35
dr. kahl on frontline therapy selection in cll
-
1:01
dr. kahl on btk inhibitor time-definite trials in cll
-
3:25
btk inhibitors in cll: treatment selection
-
3:57
btk inhibitors in chronic lymphocytic leukemia
-
1:32
dr. kahl on findings from the l-mind study with tafasitamab in dlbcl
-
0:15
copy of dr. kahl on patient preference in treatment selection for cll
-
0:54
dr. kahl on patient preference in treatment selection for cll
-
2:03
dr. kahl on considerations for treatment strategies in cll
-
1:43
dr. kahl on ibrutinib in cll
-
2:02
dr. kahl on promising research in chronic lymphocytic leukemia
-
7:11
selection of a btk inhibitor in relapsed/refractory mcl
-
1:07
dr. kahl discusses the potential of frontline ibrutinib in mcl
-
5:32
frontline antibodies with btk inhibitors for cll
-
5:50
long-term experience with btk inhibitors for cll
-
4:54
second-generation btk inhibitors in cll
-
0:58
what is your preferred btk inhibitor in cll?
-
1:33
dr. kahl on the utility of tafasitamab/lenalidomide in dlbcl
-
1:26
the expanding landscape of next-generation btk inhibitors in cll
-
1:09
dr. cohen on the potential of btk inhibitors in frontline treatment of mcl